TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oncology Institute ( (TOI) ) just unveiled an update.
The Oncology Institute has released an investor presentation highlighting its strategic plans and financial outlook. The company anticipates over 20% revenue growth in 2025 and aims to achieve EBITDA positive by the fourth quarter of 2025. The presentation outlines multiple growth channels, including strategic M&A, expanding contracts, and increasing specialty pharmacy services, which are expected to enhance the company’s market positioning and operational efficiency.
The most recent analyst rating on (TOI) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Oncology Institute stock, see the TOI Stock Forecast page.
Spark’s Take on TOI Stock
According to Spark, TipRanks’ AI Analyst, TOI is a Neutral.
The overall stock score of 45 reflects significant financial challenges, including high leverage and negative equity, which weigh heavily on the score. Despite positive earnings call highlights such as revenue growth and strategic advancements, technical indicators and valuation metrics remain weak, contributing to a cautious outlook.
To see Spark’s full report on TOI stock, click here.
More about Oncology Institute
The Oncology Institute, Inc. operates in the healthcare industry, focusing on oncology services. It provides a value-based care platform for cancer treatment, offering services such as medical oncology, radiation oncology, specialty pharmacy, and clinical research. The company aims to deliver patient-first, physician-led care with deep payor collaboration, emphasizing cost control and improved patient outcomes.
Average Trading Volume: 1,886,372
Technical Sentiment Signal: Buy
Current Market Cap: $320.7M
See more data about TOI stock on TipRanks’ Stock Analysis page.